Urology Times presents Case-Based Peer Perspectives. In each video, expert physicians provide insight on managing urology-based patient cases that highlight the use of novel agents in clinical practice.
A 74-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and A 62-Year-Old Man with High-Risk Localized Prostate Cancer
Navigating Treatment Decisions in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Optimizing Sequential Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone-Predominant Disease
A 70-Year-Old Man Diagnosed With PSMA-Positive mCRPC
Case-Based Peer Perspectives: A 65-Year-Old Man Diagnosed with PSMA-positive mCRPC
A 72-Year-Old Man with Metastatic Urothelial Carcinoma and a 76-Year-Old Man with Locally Advanced, Resectable Urothelial Carcinoma
A 66-Year-Old-Man with Prostate Cancer and a 78-Year-Old Man with Metastatic Prostate Cancer
A 67-Year-Old-Man with Metastatic Prostate Cancer
A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer and a 77-Year-Old Man With Muscle-Invasive Bladder Cancer
A 65-Year-Old Man with Prostate Cancer and a 77-Year-Old Man with Prostate Cancer
A 74-Year-Old-Man with Metastatic Prostate Cancer
A 66-Year-Old-Man with Metastatic Prostate Cancer
A 60-Year-Old Man with Prostate Cancer
A 64-Year-Old-Man with Metastatic Prostate Cancer
A 64-Year-Old Man with Elevated PSA Levels
A 75-Year-Old Woman with High-Risk Muscle Invasive Bladder Cancer
Study shows persistent bone protective effect of menopausal hormone therapy
Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC
Aquablation procedures for prostate cancer completed at ambulatory surgery center
FDA grants priority review to expanded indication of flibanserin in HSDD
Case Based Peer Perspectives